Comparison of pharmacokinetic profiles of PM02734 loaded lipid nanoparticles and cyclodextrins: In vitro and in vivo characterization

Journal of Biomedical Nanotechnology

Volumn 8, Issue 4, 2012, Pages 703-708

  Estella Hermoso De Mendoza, A ^a   Calvo, P ^b   Bishop, A ^b   Aviles P ^b   Blanco Prieto, M J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b PHARMAMAR S A   (Spain)

Author keywords

Cancer treatment; In vitro; In vivo; Lipid nanoparticles; Pharmacokinetics; PM02734

Indexed keywords

BEAGLE DOG; BROAD SPECTRUM; DELIVERY SYSTEMS; ENCAPSULATION EFFICIENCY; HIGH SHEAR; IN-VITRO; IN-VIVO; LIPID NANOPARTICLES; ORAL ADMINISTRATION; PHARMACOKINETIC PROFILES; PM02734; SOLID LIPID NANOPARTICLE (SLN); SOLID TUMORS; STABILITY STUDY; SUSTAINED RELEASE; ULTRA-SONICATION;

BIOCHEMISTRY; CYCLODEXTRINS; ENCAPSULATION; HOMOGENIZATION METHOD; ONCOLOGY; PARAMETER ESTIMATION; PHARMACOKINETICS;

NANOPARTICLES;

CYCLODEXTRIN; ELISIDEPSIN; GLYCEROL PALMITOSTEARATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STABILITY; ELUTION; EXPERIMENTAL DOG; FEMALE; HIGH SHEAR HOMOGENIZATION; HOT HOMOGENIZATION METHOD; MALE; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; SHELF LIFE; STORAGE TEMPERATURE; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRASOUND; ZETA POTENTIAL;

ANIMALS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DEPSIPEPTIDES; DOGS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; LIPIDS; MOLECULAR CONFORMATION; NANOPARTICLES; PARTICLE SIZE;

EID: 84865127085     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1420     Document Type: Article

References (25)

1. L. H. O'Hanlon, Scientists are searching the seas for cancer drugs. J. Natl. Cancer Inst. 98, 662 (2006).
2. K. L. Rinehart, Antitumor compounds from tunicates. Med. Res. Rev. 20, 1 (2000).
3. M. T. Hamann, C. S. Otto, P. J. Scheuer, and D. C. Dunbar, Kahalalides: Bioactive Peptides from a marine mollusk elysia rufescens and its algal diet bryopsis sp.(1). J. Org. Chem. 61, 6594 (1996).
4. M. L. Janmaat, J. A. Rodriguez, J. Jimeno, F. A. Kruyt, and G. Giaccone, Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 68, 502 (2005).
5. J. M. Molina-Guijarro, A. Macias, C. Garcia, E. Munoz, L. F. Garcia-Fernandez, M. David, L. Nunez, J. F. Martinez-Leal, V. Moneo, C. Cuevas, M. P. Lillo, C. Villalobos Jorge, C. Valenzuela, and C. M. Galmarini, Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS ONE 6, e19042 (2011).
6. M. Provencio, A. Sanchez, J. Gasent, and R. Rosell, Cancer treatments: Can we find treasures at the bottom of the sea. Clin. Lung. Cancer 10, 295 (2009).
7. A. L. Laza-Knoerr, R. Gref, and P. Couvreur, Cyclodextrins for drug delivery. J. Drug. Target. 18, 645 (2010).
8. T. Loftsson and J. H. Olafsson, Cyclodextrins: New drug delivery systems in dermatology. Int. J. Dermatol. 37, 241 (1998).
9. S. Comini, P. Olivier, M. Riottot, and D. Duhamel, Interaction of beta-cyclodextrin with bile acids and their competition with vitamins A and D3 as determined by 1H-NMR spectrometry. Clin. Chim. Acta 228, 181 (1994).
10. S. Gould and R. C. Scott, 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): A toxicology review. Food Chem. Toxicol. 43, 1451 (2005).
11. A. Estella-Hermoso de Mendoza, M. A. Campanero, F. Mollinedo, and M. J. Blanco-Príeto, Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotechnol. 5, 323 (2009).
12. S. A. Wissing, O. Kayser, and R. H. Muller, Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 56, 1257 (2004).
13. R. H. Muller, K. Mader, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161 (2000).
14. W. Mehnert and K. Mader, Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165 (2001).
15. J. Y. Fang, C. L. Fang, C. H. Liu, and Y. H. Su, Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 70, 633 (2008).
16. S. S. Shidhaye, R. Vaidya, S. Sutar, A. Patwardhan, and V. J. Kadam, Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr. Drug Deliv. 5, 324 (2008).
17. B. Siekmann and K. Westesen, Sub-micron sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1, 123 (1992).
18. R. Cavalli, O. Caputo, M. E. Carlotti, M. Trotta, C. Scarnecchia, and M. R. Gasco, Sterilization and freeze - Drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148, 47 (1997).
19. M. Y. Levy, W. Schutze, C. Fuhrer, and S. Benita, Characterization of diazepam submicron emulsion interface: Role of oleic acid. J. Microencapsul. 11, 79 (1994).
20. D. Hou, C. Xie, K. Huang, and C. Zhu, The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24, 1781 (2003).
21. R. Paliwal, S. Rai, B. Vaidya, K. Khatri, A. K. Goyal, N. Mishra, A. Mehta, and S. P. Vyas, Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery, Nanomedicine: Nanotechnology. Biol. Med. 5, 184 (2008).
22. H. Zhang, W. Cui, J. Bei, and S. Wang, Preparation of poly(lactide-co-glycolide-co-caprolactone) nanoparticles and their degradation behaviour in aqueous solution. Polym. Degrad. Stab. 91, 1929 (2006).
23. A. J. Almeida and E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59, 478 (2007).
24. R. Cavalli, A. Bargoni, V. Podio, E. Muntoni, G. P. Zara, and M. R. Gasco, Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J. Pharm. Sci. 92, 1085 (2003).
25. G. Suresh, K. Manjunath, V. Venkateswarlu, and V. Satyanarayana, Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm. Sci. Tech. 8, 24 (2007).